{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:38:37Z","timestamp":1788388717355,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Fundacao de Amparo a Pesquisa do Estado de Sao Paulo","doi-asserted-by":"publisher","award":["2019\/15873-6"],"award-info":[{"award-number":["2019\/15873-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cientifico e Tecnologico","doi-asserted-by":"publisher","award":["304091\/2021-9"],"award-info":[{"award-number":["304091\/2021-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.beem.2024.101922","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T02:57:47Z","timestamp":1723604267000},"page":"101922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective"],"prefix":"10.1016","volume":"39","author":[{"given":"Felipe","family":"Freitas-Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madson Q.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.beem.2024.101922_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.beem.2024.101922_bib2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101922_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.beem.2024.101922_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"6","key":"10.1016\/j.beem.2024.101922_bib5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beem.2024.101922_bib6","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.beem.2024.101922_bib7","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae078","article-title":"Pitfalls in the diagnostic evaluation of pheochromocytomas","volume":"8","author":"Fagundes","year":"2024","journal-title":"J Endocr Soc"},{"issue":"2","key":"10.1016\/j.beem.2024.101922_bib8","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac004","article-title":"Perioperative management of pheochromocytomas and sympathetic paragangliomas","volume":"6","author":"Fagundes","year":"2022","journal-title":"J Endocr Soc"},{"issue":"2","key":"10.1016\/j.beem.2024.101922_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101922_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/1471-2407-14-523","article-title":"The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study","volume":"14","author":"Schovanek","year":"2014","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.beem.2024.101922_bib11","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"European network for the study of adrenal T. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.beem.2024.101922_bib12","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2589-7500(23)00094-8","article-title":"Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort","volume":"5","author":"Pamporaki","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"2","key":"10.1016\/j.beem.2024.101922_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccell.2017.01.009","article-title":"Pheochromocytomas and paragangliomas, genetically diverse and minimalist, all at once!","volume":"31","author":"Dahia","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.beem.2024.101922_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Cancer genome atlas research N, Pacak K, Nathanson KL, Wilkerson MD. comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.beem.2024.101922_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.185","article-title":"Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","volume":"13","author":"Group NGSiPS","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101922_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.beem.2024.101922_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2024.101922_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/endrev\/bnae001","article-title":"Imaging of pheochromocytomas and paragangliomas","volume":"45","author":"Timmers","year":"2024","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.beem.2024.101922_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/cen.14467","article-title":"Genetic and clinical aspects of paediatric pheochromocytomas and paragangliomas","volume":"95","author":"Petenuci","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2024.101922_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2024.101922_bib21","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/ncomms7044","article-title":"Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas","volume":"6","author":"Castro-Vega","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2024.101922_bib22","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.beem.2024.101922_bib23","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.beem.2024.101922_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.beem.2024.101922_bib25","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-4257","article-title":"Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing","volume":"98","author":"Crona","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2024.101922_bib26","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beem.2024.101922_bib27","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa502","article-title":"Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma","volume":"105","author":"Jiang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101922_bib28","article-title":"Insights into the genetic landscape of pheochromocytomas and paragangliomas in a Brazilian cohort","volume":"Dec 17","author":"Fagundes","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2024.101922_bib29","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae038","article-title":"Patient sex and origin influence distribution of driver genes and clinical presentation of paraganglioma","volume":"8","author":"Richter","year":"2024","journal-title":"J Endocr Soc"},{"issue":"8","key":"10.1016\/j.beem.2024.101922_bib30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/jmedgenet-2020-107652","article-title":"International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma","volume":"59","author":"Ben Aim","year":"2022","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.beem.2024.101922_bib31","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1210\/jc.2004-0769","article-title":"Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma","volume":"89","author":"McWhinney","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101922_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20283","article-title":"Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot?","volume":"45","author":"Cascon","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.beem.2024.101922_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jmg.2007.054965","article-title":"Molecular characterisation of a common SDHB deletion in paraganglioma patients","volume":"45","author":"Cascon","year":"2008","journal-title":"J Med Genet"},{"issue":"10","key":"10.1016\/j.beem.2024.101922_bib34","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101922_bib35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1677\/ERC-10-0004","article-title":"Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl","volume":"17","author":"Lodish","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101922_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12688\/wellcomeopenres.10069.1","article-title":"Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN","volume":"1","author":"Fowler","year":"2016","journal-title":"Welcome Open Res"},{"issue":"4","key":"10.1016\/j.beem.2024.101922_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1399-0004.2009.01157.x","article-title":"Penetrance and clinical consequences of a gross SDHB deletion in a large family","volume":"75","author":"Solis","year":"2009","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.beem.2024.101922_bib38","doi-asserted-by":"crossref","first-page":"L23","DOI":"10.1530\/ERC-12-0399","article-title":"A founder SDHB mutation in Portuguese paraganglioma patients","volume":"20","author":"Martins","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.beem.2024.101922_bib39","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1210\/clinem\/dgad028","article-title":"Evidence for a founder effect of SDHB exon 1 deletion in Brazilian patients with paraganglioma","volume":"108","author":"Fagundes","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101922_bib40","article-title":"SDHB exon 1 deletion: a recurrent germline mutation in Colombian patients with pheochromocytomas and paragangliomas","volume":"13","author":"Manotas","year":"2022","journal-title":"Front Genet"},{"issue":"12","key":"10.1016\/j.beem.2024.101922_bib41","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1210\/jc.2016-1665","article-title":"A SDHC founder mutation causes paragangliomas (PGLs) in the French Canadians: new insights on the SDHC-related PGL","volume":"101","author":"Bourdeau","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101922_bib42","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0560","article-title":"Dutch founder SDHB exon 3 deletion in patients with pheochromocytoma-paraganglioma in South Africa","volume":"11","author":"Gordon","year":"2022","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.beem.2024.101922_bib43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1399-0004.2011.01653.x","article-title":"High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands","volume":"81","author":"Hensen","year":"2012","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/j.beem.2024.101922_bib44","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101922_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/ERC-11-0243","article-title":"False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease","volume":"19","author":"Fonte","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2024.101922_bib46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12020-020-02594-w","article-title":"SDHB large deletions are associated with absence of MIBG uptake in metastatic lesions of malignant paragangliomas","volume":"72","author":"Petenuci","year":"2021","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.beem.2024.101922_bib47","doi-asserted-by":"crossref","first-page":"L51","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.beem.2024.101922_bib48","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"10431","key":"10.1016\/j.beem.2024.101922_bib49","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2024.101922_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:50:56Z","timestamp":1738324256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1521690X24000769"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101922","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101922"}}